(Reuters) – Gilead Sciences Inc said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
Gilead files U.S. marketing application for remdesivir
Aug 10, 2020 | 10:12 AM
